Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 5/20 | 0.47 |
| ▸ | HTR1B | P28222 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | PRKCI | P41743 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10233444 | 0.84 | HTR7 (0.46) | HTR7HTR1B | |
| SCHEMBL2669105 | 0.82 | PIK3CD (0.43) | KDM4E | |
| SCHEMBL12200548 | 0.82 | MAPT (0.38) | KDM4ELMNA | |
| SCHEMBL13652939 | 0.80 | HSD17B10 (0.42) | KDM4ECYP1A2 | |
| SCHEMBL13696389 | 0.79 | HTR1B (0.39) | HTR1BKDM4ECHRNB2CHRNA4PRKCI | |
| SCHEMBL13408569 | 0.77 | PIK3CD (0.40) | HTR7HTR1BKDM4EHRH3 | |
| SCHEMBL968935 | 0.75 | HTR7 (0.46) | HTR7HTR1BHTR6KDM4ECHRNB2 | |
| SCHEMBL12636201 | 0.75 | ACACB (0.33) | KDM4E | |
| SCHEMBL10049899 | 0.74 | PDE10A (0.44) | KDM4ECYP1A2 | |
| SCHEMBL14970134 | 0.73 | L3MBTL1 (0.44) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9452977-B2 | Cyclopentylacrylamide derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2016-09-27 | — | — | US | disclosed |
| US-20150105581-A1 | CYCLOPENTYLACRYLAMIDE DERIVATIVE | TEIJIN LIMITED (JP) | 2015-04-16 | — | — | US | disclosed |
| US-8946440-B2 | Cyclopentylacrylamide derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2015-02-03 | — | — | US | disclosed |
| US-8173649-B2 | Glucokinase activator | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2012-05-08 | — | — | US | disclosed |
| US-20110160211-A1 | CYCLOPENTYLACRYLAMIDE DERIVATIVE | TEIJIN LIMITED (JP) | 2011-06-30 | — | — | US | disclosed |
| US-20100016304-A1 | GLUCOKINASE ACTIVATOR | TEIJIN LIMITED (JP) | 2010-01-21 | — | — | US | disclosed |
| WO-2009133687-A1 | CYCLOPENTYLACRYLIC ACID AMIDE DERIVATIVE | 杏林製薬株式会社 (JP) | 2009-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016304-A1 | GLUCOKINASE ACTIVATOR | GCK, GCKR, GALK1 | HTR7 2202/4885HTR1B 1758/4885HTR6 1484/4885 |
| US-20110160211-A1 | CYCLOPENTYLACRYLAMIDE DERIVATIVE | GPR119, SLC5A1, SLC5A2 | HTR7 2504/4885HTR1B 1084/4885HTR6 1327/4885 |
| US-20150105581-A1 | CYCLOPENTYLACRYLAMIDE DERIVATIVE | GPR119, SLC5A1, SLC5A2 | HTR7 2504/4885HTR1B 1084/4885HTR6 1327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.